Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wedbush Reiterates Outperform on Surface Oncology, Maintains $3 Price Target

Wedbush analyst Robert Driscoll reiterates Surface Oncology (NASDAQ:SURF) with a Outperform and maintains $3 price target.
byBenzinga Newsdesk
March 10, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Wedbush analyst Robert Driscoll reiterates Surface Oncology (NASDAQ:SURF) with a Outperform and maintains $3 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Traders Circulate Barclays Note Saying Catalent Had Their 483s Cleared Over The Weekend. The FDA Cleared Both The Belgium And Bloomington Facilities 483s With Voluntary Action Indicated Designations; A Minimally Acceptable State Of Compliance Was Met

By Benzinga Newsdesk
November 28, 1:56 PM
Barclays saying that CTLT had their 483s were cleared over the weekend the FDA cleared both the Belgium and Bloomington facilities’ 483s over the weekend with Voluntary Action Indicated (VAI) designations.

CTLT